Nuclear Medicine Department, Institut Régional du Cancer de Montpellier, University of Montpellier, Montpellier, France.
Nuclear Medicine Department, Institut Régional du Cancer de Montpellier, University of Montpellier, Montpellier, France; Institut des Biomolécules Max Mousseron, University of Montpellier, Montpellier, France.
Eur Urol Focus. 2024 Jul;10(4):514-517. doi: 10.1016/j.euf.2024.07.016. Epub 2024 Aug 13.
Metastatic prostate cancer is a frequent and fatal disease. Targeted radionuclide therapy (TRT) has become a readily available therapeutic option since the approval of [Lu]Lu-PSMA-617. Various molecules are currently being studied for TRT in prostate cancer. We review various combinations of isotopes and vectors being used to target prostate cancer cells and optimize pharmacokinetics. Promising innovations include chemical modifications to improve biodistribution, identification of new targets, and the use of novel radioisotopes such as α emitters. PATIENT SUMMARY: Our mini review summarizes research on targeted radioactive drugs for treatment of metastatic prostate cancer. Several promising radioactive pharmaceuticals are being evaluated in clinical trials, but more studies are necessary before these can be used in routine clinical practice.
转移性前列腺癌是一种常见且致命的疾病。自[Lu]Lu-PSMA-617 获得批准以来，靶向放射性核素治疗（TRT）已成为一种现成的治疗选择。目前正在研究各种分子用于前列腺癌的 TRT。我们回顾了用于靶向前列腺癌细胞和优化药代动力学的各种同位素和载体的组合。有前途的创新包括改善生物分布的化学修饰、新靶标的鉴定以及α发射体等新型放射性同位素的使用。
我们的小型综述总结了用于治疗转移性前列腺癌的靶向放射性药物的研究。几种有前途的放射性药物正在临床试验中进行评估，但在这些药物能够常规临床应用之前，还需要进行更多的研究。
